The recombinant Llama VHH-Human IgG Antibody from SignalChem Biotech is a high-sensitivity SARS-CoV-2 spike protein detection assay. The particular activity was quantified using a couple of Functional ELISA systems, and this was done by testing the binding ability of the nanobody to SARS-CoV-2 spike protein.
Scientific background
SARS-CoV-2 the severe acute respiratory syndrome-related novel coronavirus has been responsible for causing the pandemic of respiratory diseases (COVID-19) throughout the world in 2020.
1
The spike glycoprotein (S) of coronavirus is part of the type I transmembrane protein that contains two subunits, S1 and S2.
2 These subunits are also known to be the main components to attach to host cells via the interaction with angiotensin-converting enzyme 2 (ACE2).
The Anti 2019-nCoV Spike Protein Llama Heavy-Chain Antibody
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) or 2019-nCoV is a virus that triggers an ongoing outbreak of the lower respiratory tract disease known as coronavirus disease 2019 (COVID-19).
There have been over 111 million cases worldwide thus far, and the ongoing pandemic has led to an enormous amount of disruption in public health and safety.
The SARS-CoV-2 virus enters host cells by binding to the ACE2 receptor enzyme, because of this, effectively targeting the RBD-ACE2 interaction has the potential to open therapeutic avenues in the ongoing fight against the virus.
Conventional antibodies or immunoglobulins (IgG) are used as a means of therapeutic intervention, but a further subclass of IgGs from the camelid family with an unpaired heavy-chain domain has been found to facilitate competitive blocking of RBD-ACE2 binding.